Microcap Ledger Alumis Inc. $ALMS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
What the company doesAI summary of filing
Alumis Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. The company's lead product candidate, envudeucitinib (envu), is an allosteric TYK2 inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis and Phase 2 trials for systemic lupus erythematosus, with plans to submit a New Drug Application to the FDA in the second half of 2026. Alumis also develops A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory diseases, and lonigutamab, a monoclonal antibody acquired through the ACELYRIN merger for thyroid eye disease. The company is pre-revenue and relies on third-party manufacturers for its product candidates. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $3.40M | −$235.27M | −$168.58M | $63.71M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $24.05M | −$243.32M | −$369.52M | $89.67M | [10-K 2026-03-19] |
| FY ended Dec 2024 | — | −$294.23M | −$255.08M | $169.53M | [10-K 2026-03-19] |
- Quarterly cash burn
- −$84.29M
- Cash runway Estimate
- ~2.3 months
Capital structure and dilution
- Shelf registration
- S-3ASR filed 2026-03-19 [S-3ASR 2026-03-19]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-08 | Akkaraju Srinivas | sell | 48,066 | $10.55 | [4 2026-09-09] |
| 2026-09-08 | Akkaraju Srinivas | sell | 48,065 | $10.55 | [4 2026-09-09] |
| 2026-09-08 | Akkaraju Srinivas | buy | 273,291 | $10.63 | [4 2026-09-09] |
| 2026-09-08 | Akkaraju Srinivas | buy | 273,290 | $10.63 | [4 2026-09-09] |
| 2026-09-04 | Akkaraju Srinivas | buy | 220,070 | $11.17 | [4 2026-09-09] |
| 2026-09-04 | Akkaraju Srinivas | buy | 220,070 | $11.17 | [4 2026-09-09] |
| 2026-08-03 | Schroer John R. | sell | 3,282 | $26.37 | [4 2026-08-05] |
| 2026-08-03 | Pangali Sanam | sell | 1,364 | $26.37 | [4 2026-08-05] |
| 2026-08-03 | Hardiman Roy C. | sell | 2,692 | $26.37 | [4 2026-08-05] |
| 2026-08-03 | Goldstein David M | sell | 2,596 | $26.37 | [4 2026-08-05] |
| 2026-08-03 | Drappa Jorn | sell | 2,447 | $26.37 | [4 2026-08-05] |
| 2026-08-03 | Bradley Mark Christopher | sell | 2,572 | $26.37 | [4 2026-08-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-01 | 8-K | Other events |
| 2026-08-17 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-10 | 8-K | Other events |
| 2026-08-06 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-02 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-02 | 8-K | Shareholder vote results |
| 2026-06-29 | 8-K | Other events |
| 2026-05-18 | DEF 14A | Proxy statement |
| 2026-05-14 | 10-Q | Quarterly report |
Alerts for $ALMS
Email me when Alumis Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.